← All trials
NCT05460507
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Jul 15, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cytori TherapeuticsLead sponsor
- Plus TherapeuticsStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.